NASDAQ:AIFC ALT5 Sigma Q4 2025 Earnings Report $0.64 -0.08 (-11.45%) As of 06/5/2026 04:00 PM Eastern ProfileEarnings HistoryForecast ALT5 Sigma EPS ResultsActual EPS-$6.19Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AALT5 Sigma Revenue ResultsActual Revenue$5.37 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AALT5 Sigma Announcement DetailsQuarterQ4 2025Date4/11/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ALT5 Sigma Earnings HeadlinesAIFC AI Financial CorporationMay 15, 2026 | seekingalpha.comSuperQ Quantum Signs AiFi Deal for Post-Quantum Security and TokenizationMay 8, 2026 | finance.yahoo.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.June 6 at 1:00 AM | Brownstone Research (Ad)SuperQ Quantum: SuperQ Quantum Secures Major Commercial Agreement with AI Financial (AIFC) to Implement Post-Quantum Security and Compute TokenizationMay 7, 2026 | finanznachrichten.deAI Financial Corporation Announces Commercial Agreement with SuperQ Quantum to Support Post-Quantum Security InitiativesMay 7, 2026 | markets.businessinsider.comEric Trump Removed From Public Leadership Of Fintech Company With Trump Family TiesMay 2, 2026 | msn.comSee More ALT5 Sigma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALT5 Sigma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALT5 Sigma and other key companies, straight to your email. Email Address About ALT5 SigmaALT5 Sigma (NASDAQ:AIFC) Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.View ALT5 Sigma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?IREN's 800MW Bet Flips the AI Power SwitchBuy the Dip? Broadcom's AI Moat Is Wider Than EverCrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?The Market Has Ollie’s Bargain Outlet Completely Wrong Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
